CHESSMEN Board meets in Rome to discuss shortage prevention.

The Federal Office for Safety in Health Care (BASG) informs about new developments concerning counterfeits of the medicinal product Ozempic® (manufacturer: Novo Nordisk A/S). The existing BASG warnings of 12/10/2023, 19/10/2023 and 23/10/2023 remain valid. The manufacturer's mailing is supplemented with comprehensive patient information.

The Federal Office for Safety in Health Care has been informed by the ECDC (European Centre for Disease Prevention and Control) that in Hungary, in addition to the regions already announced, confirmed human WNV infections have been recorded in the Békés region.

The Federal Office for Safety in Health Care has been informed by the ECDC (European Centre for Disease Prevention and Control) that human WNV infections have been recorded in Toledo in Spain, in addition to the regions already announced.

BASG informs about current developments and necessary measures in case of counterfeiting of the medicinal product Ozempic® in German presentation.

The Federal Office for Safety in Health Care has been informed by the ECDC (European Centre for Disease Prevention and Control) that in France, in addition to the regions already announced, human WNV infections have been recorded in the Haute-Corse region.

Recall due to deviations from the manufacturing protocol

Up-to-date information from the 11.09.-14.09.2023 meeting on new approvals, extensions of indication, newly published EPARs and recently started procedures.

The Federal Office for Safety in Health Care has been informed by the ECDC (European Centre for Disease Prevention and Control) that confirmed human WNV infections have been recorded in Croatia in the regions of Brod-Posavina, Osijek-Baranja, Vukovar-Srijem and Zagreb.

Recall due to nitrosamine contamination above the permitted daily dose